Recent advances in the development of targeted drugs for hematopoietic progenitor kinase 1: An updated review

Area of Science:

• Immunology
• Medicinal Chemistry
• Oncology

Background:

• Hematopoietic progenitor kinase 1 (HPK1) is a key negative regulator of T cell receptor (TCR) signaling.
• Dysregulated TCR signaling impacts immune responses, making HPK1 a target for cancer immunotherapy.

Purpose of the Study:

• To review recent medicinal chemistry advances in small-molecule inhibitors and PROTACs targeting HPK1.
• To discuss strategies for developing novel HPK1-targeted cancer therapeutics.
• To provide an outlook on future directions and challenges in HPK1 drug discovery.

Main Methods:

• Literature review of recent studies on HPK1 inhibitors.
• Analysis of medicinal chemistry approaches for small-molecule and PROTAC development.
• Synthesis of current knowledge on HPK1 as a druggable target.

Main Results:

• Significant progress in developing small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) against HPK1.
• Diverse chemical strategies are being explored for novel HPK1 therapeutics.
• HPK1 inhibition enhances T cell receptor signaling, boosting anti-tumor immunity.

Conclusions:

• HPK1 is a promising target for T cell-based cancer immunotherapy.
• Continued medicinal chemistry efforts are crucial for advancing HPK1-targeted drugs.
• Overcoming challenges in HPK1 drug development will pave the way for new cancer treatments.